Aurisco Pharmaceutical Co.,Ltd: FDA NDC listings

Does Aurisco Pharmaceutical Co.,Ltd list GLP-1 drug products with FDA?

Yes. FDA’s NDC Directory files, read Nov 15, 2026, list 19 products naming semaglutide and tirzepatide under the labeler name “Aurisco Pharmaceutical Co.,Ltd”, in these marketing categories: BULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDING (17); BULK INGREDIENT (2). A listing is the labeler’s own submission; FDA says it does not indicate that FDA has verified the information or that the product is FDA-approved.

GLP-1 listings
19
Marketing categories
BULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDING (17); BULK INGREDIENT (2)
Drugs named
Semaglutide, Tirzepatide
Marketing start dates
Jun 30, 2023 to Jul 1, 2026

This page exists because the labeler has 2 or more compounded or bulk ingredient GLP-1 listings in FDA’s NDC files and no other page here under the same name. FDA’s NDC files give a labeler name, not an address or FEI number, so this index has not tied this labeler to any FDA inspection, letter or import record.

Listings

16812-103Not givenSemaglutidePOWDERNot given1 kg/kgBULK INGREDIENTJun 30, 2023None givenDec 31, 2027Unfinished drugs
16812-103Not givenSemaglutidePOWDERNot given5 g/5gBULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDINGJun 30, 2023None givenDec 31, 2027Unfinished drugs
16812-103Not givenSemaglutidePOWDERNot given1 g/gBULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDINGJun 30, 2023None givenDec 31, 2027Unfinished drugs
16812-103Not givenSemaglutidePOWDERNot given1 g/gBULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDINGJun 30, 2023None givenDec 31, 2027Unfinished drugs
16812-103Not givenSemaglutidePOWDERNot given1 g/gBULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDINGMar 15, 2025None givenDec 31, 2027Unfinished drugs
16812-103Not givenSemaglutidePOWDERNot given10 g/10gBULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDINGMar 15, 2025None givenDec 31, 2027Unfinished drugs
16812-103Not givenSemaglutidePOWDERNot given50 g/50gBULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDINGMar 15, 2025None givenDec 31, 2027Unfinished drugs
16812-103Not givenSemaglutidePOWDERNot given20 g/20gBULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDINGMar 15, 2025None givenDec 31, 2027Unfinished drugs
16812-103Not givenSemaglutidePOWDERNot given1 kg/kgBULK INGREDIENTJun 30, 2023None givenDec 31, 2027Unfinished drugs
16812-104Not givenTirzepatidePOWDERNot given50 g/50gBULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDINGOct 16, 2024None givenDec 31, 2027Unfinished drugs
16812-104Not givenTirzepatidePOWDERNot given10 g/10gBULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDINGOct 16, 2024None givenDec 31, 2027Unfinished drugs
16812-104Not givenTirzepatidePOWDERNot given1 g/gBULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDINGOct 16, 2024None givenDec 31, 2027Unfinished drugs
16812-104Not givenTirzepatidePOWDERNot given25 mg/25mgBULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDINGOct 16, 2024None givenDec 31, 2027Unfinished drugs
16812-104Not givenTirzepatidePOWDERNot given100 g/100gBULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDINGOct 16, 2024None givenDec 31, 2027Unfinished drugs
16812-104Not givenTirzepatidePOWDERNot given5 g/5gBULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDINGOct 16, 2024None givenDec 31, 2027Unfinished drugs
16812-104Not givenTirzepatidePOWDERNot given1 kg/kgBULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDINGOct 16, 2024None givenDec 31, 2027Unfinished drugs
16812-104Not givenTirzepatidePOWDERNot given20 g/20gBULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDINGOct 16, 2024None givenDec 31, 2027Unfinished drugs
16812-104Not givenTirzepatidePOWDERNot given500 g/500gBULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDINGJul 1, 2026None givenDec 31, 2027Unfinished drugs
16812-104Not givenTirzepatidePOWDERNot given200 g/200gBULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDINGOct 16, 2024None givenDec 31, 2027Unfinished drugs

FDA’s own words on the NDC Directory page (content current as of Mar 4, 2026):

Inclusion in the NDC Directory does not indicate that FDA has verified the information provided or that the products are FDA-approved. The content of each NDC Directory entry is the responsibility of the labeler submitting the SPL file. Assignment of an NDC number does not in any way denote FDA approval of the product. Any representation that creates an impression of FDA approval because a product has an NDC number is misleading and violates federal law. Inclusion in the NDC Directory or assignment of an NDC number does not mean a product is a drug as defined by federal law.

All GLP-1 NDC listings.

This page restates listings from FDA’s NDC Directory files as FDA publishes them. A listing is the labeler’s own submission to FDA, not an FDA approval and not a finding by this site, and it says nothing about inspections or enforcement. Follow the source link for FDA’s files. Report an error or add a company response.

Sources

Records last pulled Nov 15, 2026. Every entry links to the original public record.